2017 News Releases

Mar-10-2017

Bioblast Pharma Announces Receipt of Nasdaq Notification Regarding Stockholders’ Equity

TEL AVIV, Israel, March 10, 2017 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage, orphan disease-focused biotechnology company, announced today that it received a written notification from the Listing Qualifications Department of The NASDAQ Stock Market LLC. The notification advised that the company’s stockholders’ equity, as reported in the company’s Annual Report on Form 20-F for the fiscal year ended December 31, 2016, does not satisfy the Nasdaq Global Market conti... 

Continue reading

Feb-24-2017

Bioblast Pharma Reports Fourth Quarter and Year End 2016 Financial Results

TEL AVIV, Israel, Feb. 24, 2017 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage, orphan disease-focused biotechnology company, today announced financial results for the fourth quarter ended December 31, 2016 and other recent developments. Key Corporate Developments: Completed clinical trials: As previously announced on January 18, 2017, the Company reported the results of a six-month open label Phase 2a clinical trial that also included an additional six-month f... 

Continue reading

Feb-01-2017

Bioblast Pharma Provides Clinical and Development Updates on Trehalose as a Potential Therapeutic for OPMD and Other Neurodegenerative Diseases

Investor Lunch and Live Webcast at 12 noon Eastern Time Tomorrow TEL AVIV, Israel, Feb. 01, 2017 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. (NasdaqGM:ORPN), a clinical-stage, orphan disease-focused biotechnology company, announced new clinical and development updates related to its proprietary intravenous (IV) form of trehalose 90 mg/mL solution, which is being evaluated as a potential therapeutic, initially for oculopharyngeal muscular dystrophy (OPMD). Bioblast management will provide a co... 

Continue reading

Jan-26-2017

Bioblast Pharma to Host Key Opinion Leader Lunch Focused on Orphan Neurological Diseases on February 2

Investor Lunch and Live Webcast at 12 Noon Eastern Time on February 2 TEL AVIV, Israel, Jan. 26, 2017 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage, orphan disease-focused biotechnology company, will host a KOL lunch on the subject of orphan neurological diseases and treatments at 12pm on Thursday, February 2, 2017 in New York City. Bioblast management will provide an overview of the Company’s ongoing clinical development work with trehalose 90 mg/mL IV solution,... 

Continue reading

Jan-18-2017

Bioblast Announces Phase 2a Results of Trehalose in Patients with Spinocerebellar Ataxia Type 3 (SCA3)

Patients Treated with Trehalose Remained Stable According to a Well-Established Clinical Evaluation Scale A Recent Natural History Study in The Lancet Neurology in Patients with SCA3 Noted a Steady Disease Progression Over Time              TEL AVIV, Israel, Jan. 18, 2017 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage, orphan disease-focused biotechnology company, today announced results of a six-month open label Phase 2a study that also included an additional six-m... 

Continue reading